EDDING GENOR (06998) Announces First Patient Dosed in Phase II Trial for EDP167

Stock News

Yesterday

EDDING GENOR (06998) has announced that the first patient has been dosed in a Phase II clinical trial for its innovative small nucleic acid drug, EDP167. The Phase II trial is a multicenter, dose-exploration, open-label study focusing on adult patients with homozygous familial hypercholesterolemia (HoFH). The study is designed to assess the efficacy and safety of EDP167 in HoFH patients, with the primary endpoint being the change in low-density lipoprotein cholesterol (LDL-C) levels from the baseline after 24 weeks following the initial dose. Evaluation of the primary endpoint is anticipated to be completed in the fourth quarter of 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1136437227"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1136437227\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1136437227?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-09 08:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1136437227","market":"sg","top_or_hot":-1,"title":"EDDING GENOR (06998) Announces First Patient Dosed in Phase II Trial for EDP167","media":"Stock News","content":"<p>EDDING GENOR (06998) has announced that the first patient has been dosed in a Phase II clinical trial for its innovative small nucleic acid drug, EDP167. The Phase II trial is a multicenter, dose-exploration, open-label study focusing on adult patients with homozygous familial hypercholesterolemia (HoFH). The study is designed to assess the efficacy and safety of EDP167 in HoFH patients, with the primary endpoint being the change in low-density lipoprotein cholesterol (LDL-C) levels from the baseline after 24 weeks following the initial dose. Evaluation of the primary endpoint is anticipated to be completed in the fourth quarter of 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EDDING GENOR (06998) Announces First Patient Dosed in Phase II Trial for EDP167</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEDDING GENOR (06998) Announces First Patient Dosed in Phase II Trial for EDP167\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-02-09 08:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>EDDING GENOR (06998) has announced that the first patient has been dosed in a Phase II clinical trial for its innovative small nucleic acid drug, EDP167. The Phase II trial is a multicenter, dose-exploration, open-label study focusing on adult patients with homozygous familial hypercholesterolemia (HoFH). The study is designed to assess the efficacy and safety of EDP167 in HoFH patients, with the primary endpoint being the change in low-density lipoprotein cholesterol (LDL-C) levels from the baseline after 24 weeks following the initial dose. Evaluation of the primary endpoint is anticipated to be completed in the fourth quarter of 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06998","symbol_name":"亿腾嘉和","start_time":0,"source_url":"","article_id":"1136437227","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1136437227","pubTimestamp":1770597361,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"EDDING GENOR (06998) has announced that the first patient has been dosed in a Phase II clinical trial for its innovative small nucleic acid drug, EDP167. The Phase II trial is a multicenter,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06998":"亿腾嘉和","BK1574":"生物医药B类股","BK1161":"生物科技","BK1583":"高瓴概念"},"translate_title":"EDDING GENOR(06998)宣布EDP167 II期试验首例患者给药","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06998":1},"content_text":"EDDING GENOR (06998) has announced that the first patient has been dosed in a Phase II clinical trial for its innovative small nucleic acid drug, EDP167. The Phase II trial is a multicenter, dose-exploration, open-label study focusing on adult patients with homozygous familial hypercholesterolemia (HoFH). The study is designed to assess the efficacy and safety of EDP167 in HoFH patients, with the primary endpoint being the change in low-density lipoprotein cholesterol (LDL-C) levels from the baseline after 24 weeks following the initial dose. Evaluation of the primary endpoint is anticipated to be completed in the fourth quarter of 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}